NASDAQ:PTGX

Protagonist Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy PTGX

*Your capital is at risk

$118.96

+3.93 (+3.42%)

At Close: Jun 23, 2026

Protagonist Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -84.12. In total, the insiders bought 1.18M and sold 565.07K PTGX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-84.12
● Buy	1.18M shares
● Sell	565.07K shares
65% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence Jan 20, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -84.12. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 10, 2026 Sell	Common Stock S-Sale	Waddill William D. Director	Director	9 000 Value: $969.1K
Jun 10, 2026 Buy	Common Stock M-Exempt	Waddill William D. Director	Director	3 000 Value: $35.4K
Jun 10, 2026 Buy	Common Stock M-Exempt	Waddill William D. Director	Director	6 000 Value: $99.2K
Jun 10, 2026 Buy	Stock Option (right to buy) M-Exempt	Waddill William D. Director	Director	6 000 Value: $99.2K
Jun 10, 2026 Buy	Stock Option (right to buy) M-Exempt	Waddill William D. Director	Director	3 000 Value: $35.4K
May 29, 2026 Buy	Stock Option (right to buy) M-Exempt	Waddill William D. Director	Director	9 000 Value: $106.2K
May 29, 2026 Buy	Common Stock M-Exempt	Waddill William D. Director	Director	9 000 Value: $106.2K
May 29, 2026 Sell	Common Stock S-Sale	Waddill William D. Director	Director	9 000 Value: $896.8K
May 12, 2026 Buy	Stock Option (right to buy) M-Exempt	Patel Dinesh V Ph D President And CEO	CEO / President	75 000 Value: $1.62M
May 12, 2026 Sell	Common Stock S-Sale	Patel Dinesh V Ph D President And CEO	CEO / President	75 000 Value: $7.51M
May 12, 2026 Buy	Common Stock M-Exempt	Patel Dinesh V Ph D President And CEO	CEO / President	75 000 Value: $1.62M
May 08, 2026 Sell	Common Stock S-Sale	Giraudo Bryan Director	Director	5 130 Value: $513.0K
May 08, 2026 Sell	Common Stock S-Sale	Giraudo Bryan Director	Director	6 000 Value: $600.0K
May 07, 2026 Buy	Common Stock M-Exempt	Giraudo Bryan Director	Director	24 000 Value: $154.8K
May 07, 2026 Buy	Common Stock M-Exempt	Giraudo Bryan Director	Director	12 000 Value: $83.8K
May 07, 2026 Sell	Common Stock S-Sale	Giraudo Bryan Director	Director	36 000 Value: $3.61M
May 07, 2026 Sell	Common Stock S-Sale	Giraudo Bryan Director	Director	12 000 Value: $1.20M
May 07, 2026 Buy	Stock Option (right to buy) M-Exempt	Giraudo Bryan Director	Director	12 000 Value: $83.8K
May 07, 2026 Buy	Stock Option (right to buy) M-Exempt	Giraudo Bryan Director	Director	24 000 Value: $154.8K
Apr 23, 2026 Sell	Common Stock G-Gift	Patel Dinesh V Ph D President And CEO	CEO / President	1 460 Value: $0
Apr 20, 2026 Sell	Common Stock S-Sale	Ali Asif Chief Financial Officer	C-Suite Officer	1 750 Value: $184.6K
Mar 26, 2026 Sell	Common Stock S-Sale	Ali Asif Chief Financial Officer	C-Suite Officer	24 765 Value: $2.58M
Mar 26, 2026 Buy	Common Stock M-Exempt	Ali Asif Chief Financial Officer	C-Suite Officer	19 500 Value: $374.2K
Mar 26, 2026 Buy	Common Stock M-Exempt	Ali Asif Chief Financial Officer	C-Suite Officer	5 265 Value: $64.1K
Mar 26, 2026 Buy	Stock Option (right to buy) M-Exempt	Selick Harold E Director	Director	24 000 Value: $309.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorder...

Read Full Profile Here